NCT01636687

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 182 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.

Conditions

• Plaque-type Psoriasis

Interventions

Type	Name	Description
DRUG	Placebo	2 injections of placebo to secukinumab 150mg per dose
DRUG	Secukinumab 150mg	Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose were administered
DRUG	Secukinumab 300mg	Secukinumab 300mg (2 injections of 150mg secukinumab per dose)

Timeline

• Start date: 2012-10-17
• Primary completion: 2016-10-27
• Completion: 2016-10-27
• First posted: 2012-07-10
• Last updated: 2018-09-27
• Results posted: 2018-09-27

Locations

39 sites across 5 countries: United States, Canada, Estonia, France, Germany

Regulatory

• FDA-regulated drug study